ADMA Biologics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

4Q 2023 Total Revenue of $73.9 Million; FY 2023 Total Revenue of $258.2 Million4Q 2023 Adjusted EBITDA(1) of $18.6 Million; FY 2023 Adjusted EBITD...

Related Keywords

Boca Raton ,Florida ,United States ,Adam Grossman ,Michelle Pappanastos ,Biologics Inc ,Drug Administration ,Nasdaq ,Exchange Commission ,Business Development ,Net Income ,Revenue Guidance Increased ,More Than ,Income Guidance Increased ,Growth Opportunities Targeting Manufacturing ,New Pipeline Hyperimmune Globulin ,Advance During ,Call Scheduled ,Chief Executive Officer ,Growth Opportunities ,Production Yield Enhancement ,Pipeline Introduction ,Hyperimmune Globulin ,United States Food ,Adverse Reactions ,Private Securities Litigation Reform Act ,Corporate Strategy ,Managing Director ,Argot Partners ,Months Ended December ,Ended December ,